EUVIMEDEUVIMED entdecken
Crossref

Prior adalimumab exposure alters infliximab pharmacokinetics and trough targets in pediatric Crohn’s disease

Yiyoung Kwon iD, Yoon Zi Kim iD, Tae Jong Jeong iD, Yon Ho Choe iD, Mi Jin Kim iD

Inflammatory Bowel Diseases · 12.08.2026

DOI: 10.1093/ibd/izag146 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Inflammatory Bowel Diseases, online erschienen am 12.08.2026. Verfasst von Yiyoung Kwon und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pediatrics, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea. Die Arbeit nennt 21 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

In patients with Crohn’s disease (CD) treated with infliximab (IFX), the annual rate of loss of response is approximately 10%. This study aimed to compare patients who initiated primary IFX in the disease course with those who received IFX as a second-line biologic after a longer disease duration and greater prior treatment exposure.

Methods

This retrospective study reviewed medical records of children with Crohn’s disease (CD) who received IFX therapy. Patients were classified according to prior adalimumab (ADL) exposure status, and IFX trough levels (TLs) and endoscopic outcomes were compared between groups.

Results

A total of 469 children with CD were included, including 372 in the biologic-naive group and 97 in the ADL-exposed group. There was no statistically significant difference in demographic data and disease severity at diagnosis between the two groups. However, at the time of IFX initiation, patients in group 2—who had a longer disease duration—were significantly older (P < .001) and had a higher body mass index than those in group 1 (P < .001). As the 1-year outcome of IFX therapy, the proportion achieving endoscopic remission (ER) did not differ significantly between group 1 and group 2 (61.3% vs 58.8%; P = .328). However, at the 1-year assessment, IFX TLs were significantly lower in group 2 than in group 1 (4.73 µg/mL vs 6.19 µg/mL, P = .003), and a significantly higher proportion of group 2 required dose intensification (41.2% vs 35.2%; P = .001). In a combined-cohort logistic regression, erythrocyte sedimentation rate, body mass index, IFX TLs, and dose intensification were significantly associated with ER.

Conclusions

Prior ADL exposure was associated with lower IFX TLs despite comparable rates of ER when IFX was used as first- or second-line biologic therapy in pediatric CD. Patients with prior ADL exposure achieved ER at lower observed IFX TLs than biologic-naive patients, suggesting a potential difference in the exposure–response relationship according to prior ADL exposure status.

Schlagwörter

Stichwörter der Autor:innen

Crohn’s diseaseendoscopic remissioninfliximabtrough levels

Autor:innen und Institutionen

  • Department of Pediatrics, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea.

ORCID-Profile: Yiyoung Kwon, Yoon Zi Kim, Tae Jong Jeong, Yon Ho Choe, Mi Jin Kim

Zitieren

APA

Kwon, Y., Kim, Y. Z., Jeong, T. J., Choe, Y. H., & Kim, M. J. (2026). Prior adalimumab exposure alters infliximab pharmacokinetics and trough targets in pediatric Crohn’s disease. Inflammatory Bowel Diseases. https://doi.org/10.1093/ibd/izag146

Vancouver

Kwon Y, Kim YZ, Jeong TJ, Choe YH, Kim MJ. Prior adalimumab exposure alters infliximab pharmacokinetics and trough targets in pediatric Crohn’s disease. Inflammatory Bowel Diseases. 2026. doi:10.1093/ibd/izag146

BibTeX
@article{Kwon2026,
  author = {Kwon, Yiyoung and Kim, Yoon Zi and Jeong, Tae Jong and Choe, Yon Ho and Kim, Mi Jin},
  title = {Prior adalimumab exposure alters infliximab pharmacokinetics and trough targets in pediatric Crohn’s disease},
  journal = {Inflammatory Bowel Diseases},
  year = {2026},
  doi = {10.1093/ibd/izag146}
}
Kostenlos starten →